 |
Novartis AG
P.O. Box
CH 4002 Basel
|
|
US Securities and Exchange
Commission
100 F Street, N.E.
Washington, DC 20549
Basel, February 4, 2026
|
|
|
Re:
|
Notice of disclosure filed in Annual Report on Form 20-F under Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Securities Exchange Act of 1934
|
|
Ladies and
Gentlemen:
Pursuant to Section 219 of the Iran Threat Reduction and Syria Human
Rights Act of 2012 and Section 13(r) of the Securities Exchange Act of 1934, as amended, notice is hereby provided that Novartis AG has made disclosure pursuant to those provisions in its Annual Report on Form 20-F for the year ended
December 31, 2025, which was filed with the Securities and Exchange Commission on February 4, 2026.
Respectfully submitted,
Novartis AG
|
|
|
/s/ Karen L. Hale
|
/s/ Harry Kirsch
|
|
|
|
Karen L. Hale
Chief Legal & Compliance Officer of Novartis |
|
Harry Kirsch
Chief Financial Officer of Novartis |
|